Zealand Pharma Announces Once-Daily Lyxumia(R) (lixisenatide) Approved in Europe for the Treatment of Type 2 Diabetes

Zealand Pharma Announces Once-Daily Lyxumia(R) (lixisenatide) Approved in
Europe for the Treatment of Type 2 Diabetes

Under the Agreement With Sanofi, the Company is Entitled to Tiered Low
Double-Digit Percentage Royalties on Global Sales of Lyxumia(R)

COPENHAGEN, Denmark, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Zealand Pharma (NASDAQ
OMX Copenhagen: ZEAL) announces that its partner Sanofi (EURONEXT: SAN and
NYSE: SNY) has been granted a Marketing Authorization in Europe for Lyxumia®
(lixisenatide) by the European Commission.

Lyxumia®, the once-daily prandial GLP-1 receptor agonist, was invented by
Zealand Pharma and licensed to Sanofi, which holds global commercial rights
for the drug. Lyxumia® has been indicated for the treatment of Type 2 diabetes
in adults to achieve glycemic control in combination with oral
glucose-lowering medicinal products and/or basal insulin when these, together
with diet and exercise, do not provide adequate glycemic control.

The European Commission's decision to grant Marketing Authorization in Europe
for Lyxumia® is based on results from Sanofi's international GetGoal Phase III
program, involving more than 5,000 patients with Type 2 diabetes in 11
clinical studies. As part of the program, a large number of patients were
studied for an evaluation of the effects of Lyxumia® in combination with basal
insulin (706 patients treated with Lyxumia® in three trials) ^ 1.

Results from GetGoal have enabled Lyxumia® to become the first once-daily
GLP-1 receptor agonist with a predominantly prandial glucose lowering effect
to be indicated for use on top of basal insulin and in combination with oral
anti-diabetic medications. The results showed that treatment with Lyxumia®
gave significant HbA1c reductions, a pronounced lowering of post-prandial
glucose (after meal blood sugar levels) and a beneficial effect on body weight
in adult patients with Type 2 diabetes. GetGoal results also showed that
Lyxumia® had a favorable safety and tolerability profile in most patients,
with mild and transient nausea and vomiting, the most common adverse events
observed in the GLP-1 receptor agonist class, and a limited risk of
hypoglycemia.

Commenting on this announcement, David Solomon, President and CEO of Zealand
Pharma, said:"The European approval of Lyxumia® is a key milestone for
Zealand Pharma. The achievement of commercial status is the ultimate
endorsement of Lyxumia's therapeutic potential and a validation of Zealand
Pharma's peptide drug discovery and development capabilities. We are extremely
gratified that our first discovered product, lixisenatide – branded as
Lyxumia® by Sanofi, will soon be available for diabetes patients throughout
Europe."

"In clinical practice today, there is a strong need for more differentiated
diabetes treatments. Patients with Type 2 diabetes are not all alike and the
availability of additional GLP-1-based drugs with new pharmacological profiles
is important to ensure a more effective management of diabetes," said Dr Filip
K. Knop, MD, PhD, of Gentofte Hospital, University of Copenhagen. "One issue
is that patients treated with basal insulin often move away from their target
HbA1c despite well-controlled fasting plasma glucose. Adding a short acting
GLP-1 receptor agonist with a pronounced effect on post-prandial glucose like
once-daily Lyxumia® may be a good way of getting these patients back at target
without increasing the risk of hypoglycemia."

"With the European approval of Lyxumia®, we now have a simple new tool to help
patients with Type 2 diabetes further reduce HbA1c, with the benefit of weight
loss and limited risk of hypoglycaemia. This well-tolerated therapy is of
specific interest to patients who are on oral treatments and / or basal
insulin and do not manage to maintain their HbA1c targets," said Pierre
Chancel, Senior Vice-President, Global Diabetes at Sanofi in a press release
from Sanofi today. "With a single daily injection and only one step to
maintenance dose, Lyxumia® is a positive addition to the Sanofi portfolio, and
represents another step forward in our efforts to advance scientific
excellence and develop new therapeutic solutions that improve outcomes for
people with diabetes, an area of significant unmet medical need."

Marketing Authorization for Lyxumia® in Europe is applicable to the 27 Member
States of the European Union, as well as Iceland, Lichtenstein and Norway, and
follows the positive recommendation issued by the Committee for Medicinal
Products for Human Use of the European Medicines Agency on 15 November 2012.

Applications for regulatory approval of Lyxumia® in Type 2 diabetes have also
been submitted in several other countries around the world and are currently
under review. In the US, a decision on NDA filing acceptance is expected from
the FDA in Q1 2013.

Financial guidance for 2013 and the terms of the Sanofi agreement

As earlier announced, there is no milestone payment to Zealand Pharma
associated with the approval of Lyxumia® in Europe. The company will provide
financial guidance for 2013 in connection with the release of its 2012
full-year announcement on 14 March 2013.

Under the license agreement with Sanofi, which covers lixisenatide and
combination products, including lixisenatide, Zealand Pharma is eligible to
receive remaining development, regulatory and sales milestone payments of up
to USD 215 million, which include USD 40 million for a depot formulation of
Lyxumia® not currently in active development ^2.

Further, the company is entitled to tiered low double-digit percentage
royalties on global net sales of Lyxumia® and fixed low double-digit
percentage royalties on full net sales of combination products, including
lixisenatide ^2.

References

1.http://clinicaltrials.gov/ct2/results?term=GetGoal. Date accessed:
    December 2012.
2.Zealand Pharma pays 13% to Alkermes (former Elan) and 0.5% to SIP®
    technology inventor on all income from lixisenatide.

For further information, please contact:

David H. Solomon, President and Chief Executive Officer

Tel: +45 2220 6300

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication

Tel: +45 5060 3689, email: hlh@zealandpharma.com

About lixisenatide (Lyxumia®)

Lixisenatide (Lyxumia®) is a glucagon-like peptide-1 receptor agonist (GLP-1
RA) for the treatment of patients with Type 2 diabetes mellitus. GLP-1 is a
naturally-occurring peptide hormone that is released within minutes after
eating a meal. It is known to stimulate glucose-dependent insulin secretion by
pancreatic beta cells and suppress glucagon secretion from pancreatic alpha
cells..

Lixisenatide is invented by Zealand Pharma and global rights to the product
are licensed to Sanofi. Lyxumia® is the proprietary name approved by the
European Medicines Agency (EMA) for the GLP-1 RA lixisenatide.

About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company
based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery,
optimization and development of novel peptide drugs and has a broad and mature
pipeline of drug candidates identified through its own drug discovery
activities. The company's focus lies in the field of diabetes/metabolic
diseases, and its lead drug invention is lixisenatide (Lyxumia®), a once-daily
GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2
diabetes. Lyxumia® is approved in Europe (February 2013), and under regulatory
review in a large number of other countries globally. In the US, a decision on
NDA filing acceptance is expected from the FDA in Q1 2013.

Zealand Pharma has a partnering strategy for the development and
commercialization of its products and in addition to the collaboration with
Sanofi in Type 2 diabetes, the company has partnerships with Boehringer
Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced
diarrhea and AbbVie in acute kidney injury. Zealand Pharma focuses its
activities in disease areas where existing treatments fail to adequately serve
patient needs and where the market potential for improved treatments through
the use of peptide drugs is high. For further information:
www.zealandpharma.com

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including innovative blood glucose monitoring
systems. Sanofi markets both injectable and oral medications for people with
Type 1 or Type 2 diabetes.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Attachments:

02-13_0204 - Lyxumia EU Marketing Authorization - UK_Final.pdf
 
Press spacebar to pause and continue. Press esc to stop.